-
1.发明申请ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINES SUBSTITUTED WITH FLAVONES, AND INTERMEDIATES THEREOF 有权用氟化物取代吡咯烷酮的自由基合成及其中间体公开(公告)号：US20100113803A1
公开(公告)日：2010-05-06
申请号：US12307645
申请日：2006-07-07
IPC分类号： C07D207/08
CPC分类号： C07D207/08 , C07D405/04
摘要： The present invention relates to an enantioselective synthesis of (+)-trans enantiomer of pyrrolidines substituted with flavones, represented by Formula 1 or salts thereof, which are inhibitors of cyclin dependant kinases and can be used for treatment of proliferative disorders such as cancer. wherein Ar has the meaning as indicated in the claims.
摘要翻译： 本发明涉及由作为细胞周期蛋白依赖性激酶抑制剂的式1或其盐所代表的黄酮取代的吡咯烷的（+） - 反式对映异构体的对映选择性合成，可用于治疗增殖性疾病例如癌症。 其中Ar具有如权利要求中所示的含义。
-
2.发明授权Enantioselective synthesis of pyrrolidines substituted with flavones, and intermediates thereof 有权用黄酮取代的吡咯烷的对映选择性合成及其中间体公开(公告)号：US07951961B2
公开(公告)日：2011-05-31
申请号：US12307645
申请日：2006-07-07
IPC分类号： C07D295/00
CPC分类号： C07D207/08 , C07D405/04
摘要： The present invention relates to an enantioselective synthesis of (+)-trans enantiomer of pyrrolidines substituted with flavones, represented by Formula 1 or salts thereof, which are inhibitors of cyclin dependant kinases and can be used for treatment of proliferative disorders such as cancer wherein Ar has the meaning as indicated in the claims.
摘要翻译： 本发明涉及用作为细胞周期蛋白依赖性激酶抑制剂的式1或其盐所代表的黄酮取代的吡咯烷的（+） - 反式对映异构体的对映选择性合成，可用于治疗增殖性疾病如癌症，其中Ar 具有如权利要求中所示的含义。
-
3.发明申请NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS 有权用于治疗增生性疾病的新型全身纯化合物公开(公告)号：US20100179210A1
公开(公告)日：2010-07-15
申请号：US12305815
申请日：2006-06-21
申请人： Meenakshi Sivakumar , Malcolm Mascarenhas , Ankush Sarde , Pramod Kumar Jadhav , Manoj Shukla , Kalpana Joshi , Maggie Rathos
发明人： Meenakshi Sivakumar , Malcolm Mascarenhas , Ankush Sarde , Pramod Kumar Jadhav , Manoj Shukla , Kalpana Joshi , Maggie Rathos
IPC分类号： A61K31/4025 , C07D405/00 , C07D207/04 , A61P35/00
CPC分类号： C07D405/04 , C07D207/08
摘要： The present invention relates to an enantiomerically pure (+)-trans-enantiomer of a compound represented by the following formula (I): wherein R1, R2, R3, R4 and R9 are as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to a pharmaceutical composition comprising the enantiomerically pure compound. The compound of formula (I) is useful for the treatment of diseases or disorders mediated by the inhibition of cyclin dependant kinase, such as cancer.
摘要翻译： 本发明涉及由下式（I）表示的化合物的对映体纯的（+） - 反式对映异构体：其中R1，R2，R3，R4和R9如说明书中所定义; 对映体纯的中间体，用于制备对映体纯的化合物及其中间体的方法，以及包含对映体纯的化合物的药物组合物。 式（I）化合物可用于治疗由抑制细胞周期蛋白依赖性激酶（例如癌症）介导的疾病或病症。
-
4.发明授权公开(公告)号：US08563596B2
公开(公告)日：2013-10-22
申请号：US12305815
申请日：2006-06-21
申请人： Meenakshi Sivakumar , Malcolm Mascarenhas , Ankush Sarde , Pramod Kumar Jadhav , Manoj Shukla , Kalpana Joshi , Maggie Rathos
发明人： Meenakshi Sivakumar , Malcolm Mascarenhas , Ankush Sarde , Pramod Kumar Jadhav , Manoj Shukla , Kalpana Joshi , Maggie Rathos
IPC分类号： A01N43/36 , A61K31/40 , C07D405/00 , C07D409/00 , C07D411/00 , C07D207/00
CPC分类号： C07D405/04 , C07D207/08
摘要： The present invention relates to an enantiomerically pure (+)-trans enantiomer of a compound represented by the following formula (I): wherein R1, R2, R3, R4 and R9 are as defined in the specification; enantiomerically pure intermediates thereof, to processes for the preparation of the enantiomerically pure compound and its intermediates, and to a pharmaceutical composition comprising the enantiomerically pure compound. The compound of formula (I) is useful for the treatment of diseases or disorders mediated by the inhibition of cyclin dependant kinase, such as cancer.
摘要翻译： 本发明涉及由下式（I）表示的化合物的对映体纯的（+） - 反式对映异构体：其中R1，R2，R3，R4和R9如说明书中所定义; 对映体纯的中间体，用于制备对映体纯的化合物及其中间体的方法，以及包含对映体纯的化合物的药物组合物。 式（I）化合物可用于治疗由抑制细胞周期蛋白依赖性激酶（例如癌症）介导的疾病或病症。
-
-
-
搜索结果
4 条记录 (耗时 0.02 秒)
